{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Inflammation can alter mood and contribute to defined depressive syndromes; a causal high-inflammation MDD subtype still needs prospective confirmation.",
  "implications": "Overall Γ follows registered SC3. Baseline prediction is Β, and sustained immune-treatment-related syndromes earn a restricted Ε at SC2. Neither narrow immune exposure nor exploratory high-CRP response establishes prospectively identifiable inflammatory MDD causation. Genuine positive clinical pilot findings are retained alongside larger or prospectively stratified nulls. The next clinical subtype boundary remains open rather than being declared refuted.",
  "limitations": "56 primary reports with 5 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}